达沙替尼与高剂量伊马替尼治疗标准剂量伊马替尼耐药患者慢性髓系白血病的成本效益分析

{"title":"达沙替尼与高剂量伊马替尼治疗标准剂量伊马替尼耐药患者慢性髓系白血病的成本效益分析","authors":"J. Darbá, Lisette Kaskens","doi":"10.1007/BF03320875","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":101511,"journal":{"name":"PharmacoEconomics Spanish Research Articles","volume":"54 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2012-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Análisis coste-efectividad de dasatinib frente a imatinib a dosis alta en el tratamiento de la leucemia mieloide crónica en pacientes resistentes a dosis estándar de imatinib\",\"authors\":\"J. Darbá, Lisette Kaskens\",\"doi\":\"10.1007/BF03320875\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":101511,\"journal\":{\"name\":\"PharmacoEconomics Spanish Research Articles\",\"volume\":\"54 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PharmacoEconomics Spanish Research Articles\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/BF03320875\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics Spanish Research Articles","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF03320875","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}